Home ivps4 2017-06-16T21:39:52+00:00

News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Investor Alerts

Mar 13, 2020

Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
Mar 12, 2020

Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
Mar 3, 2020

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020
Feb 6, 2020

Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users
Jan 13, 2020

Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery
Dec 19, 2019

Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
Dec 17, 2019

Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
Dec 9, 2019

Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
Nov 6, 2019

Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
Oct 31, 2019

Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
Oct 24, 2019

Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
Sep 30, 2019

Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
Sep 13, 2019

Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Sep 5, 2019

Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
Sep 4, 2019

Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
Aug 8, 2019

/C O R R E C T I O N -- Achieve Life Sciences, Inc./
Jul 30, 2019

Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
Jul 23, 2019

Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
Jun 21, 2019

Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Jun 11, 2019

Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
Jun 3, 2019

Achieve Receives $4.2 Million from Exercise of Warrants
May 30, 2019

Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
May 15, 2019

Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
May 7, 2019

Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
Apr 24, 2019

Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

Topline data from ORCA-1 trial expected in the Second Quarter of 2019
Apr 3, 2019

Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
Apr 2, 2019

Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

Topline data from ORCA-1 trial expected in the Second Quarter of 2019
Mar 18, 2019

Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
Mar 14, 2019

Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
Mar 5, 2019

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
Feb 22, 2019

Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting
Feb 20, 2019

Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation

Topline data from ORCA-1 trial expected in mid-2019
Dec 18, 2018

Achieve Announces Update on Cytisinicline Clinical Development Program
Nov 7, 2018

Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update
Oct 31, 2018

Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
Oct 30, 2018

Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation
Oct 1, 2018

Achieve Announces Pricing of $5.6 Million Registered Direct Offering
Sep 27, 2018

Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed and Fasted Subjects
Sep 26, 2018

Achieve to Present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018
Sep 18, 2018

Achieve Announces Positive Cytisine Data Published in International Journal of Drug Policy

Cytisine Demonstrated Superior Abstinence Rates Compared to Nicotine Replacement Therapy
Sep 6, 2018

Achieve Life Sciences Announces Cytisine Data Presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference
Sep 5, 2018

Achieve to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 6, 2018
Aug 8, 2018

Achieve Reports Financial Results for Second Quarter 2018 and Provides Cytisine Clinical Development Update
Aug 2, 2018

Achieve Life Sciences to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 8, 2018
Jul 11, 2018

Achieve Life Sciences Announces Advancement of Cytisine Development Program Following Meeting with the FDA
Jun 26, 2018

Achieve Announces Positive Cytisine Data Demonstrating No Clinically Significant Drug-Drug Interaction
Jun 19, 2018

Achieve Life Sciences, Inc. Announces Closing of a $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Jun 15, 2018

Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
Jun 11, 2018

Achieve Announces Publication of Cytisine Data for Next-Generation Cytisine Molecules
May 23, 2018

Achieve Life Sciences, Inc. Announces Reverse Stock Split
May 9, 2018

Achieve Reports Financial Results for First Quarter 2018
May 7, 2018

Achieve Announces Patent Granted on Novel Formulation of Cytisine
Mar 6, 2018

Achieve Life Sciences Announces Cytisine Symposium at the 17th World Conference on Tobacco or Health
Mar 1, 2018

Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results
Feb 20, 2018

Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
Jan 24, 2018

Achieve Announces Expansion of Partnership with the University of Bristol for Next Generation Cytisine-Based Therapies to Include Exclusive Rights for Cytisine Development Across Multiple Therapeutic Categories
Nov 28, 2017

Achieve Announces Clinical Trial Supply and Cooperation Agreement with the University of Auckland for the Evaluation of Cytisine Compared to Varenicline for Smoking Cessation
Nov 14, 2017

Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects
Nov 9, 2017

Achieve Reports Financial Results for Third Quarter 2017
Nov 8, 2017

Achieve to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28th, 2017
Nov 6, 2017

Achieve Announces Availability of Company Presentation from the Virtual Investor Conference
Oct 30, 2017

Achieve Announces Company Presentation at Virtual Investor Conference on November 2, 2017

Company invites individual and institutional investors and advisors to attend virtualinvestorconferences.com
Oct 26, 2017

Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine
Oct 4, 2017

Achieve Announces Advancement of Cytisine Clinical Development Program

Rapid Progress on Advancing Clinical Program with Commencement of Pharmacokinetic (PK) & Pharmacodynamic (PD) Cytisine Study and Completion of Enrollment in Food Effect PK Study
Sep 14, 2017

Achieve Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
Aug 16, 2017

Achieve Announces Initiation of Cytisine Clinical Development Program
Aug 10, 2017

Achieve Announces FDA Acceptance of the Investigational New Drug Application (IND) for Cytisine as a Smoking Cessation Treatment
Aug 1, 2017

Achieve Life Sciences Announces Closing of Merger with OncoGenex Pharmaceuticals
Jun 13, 2017

Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC

Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for August 1, 2017
Mar 8, 2017

Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")

Professor Nancy Rigotti, MD, will chair a symposium entitled "Cytisine Update: Moving Research Forward Toward a Globally Affordable Tobacco Cessation Medication"
Mar 1, 2017

Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National Institutes of Health to Advance the Development of Cytisine for Smoking Cessation

Ongoing IND-enabling Non-clinical Program to Support the Use of Cytisine in Smoking Cessation
Jan 5, 2017

OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement

Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization of Cytisine for Smoking Cessation

Show per page

Stock Info